Efficacy, safety, and molecular response predictors of oral ixazomib and short-course rituximab in untreated iNHL.
Ontology highlight
ABSTRACT: Patients with indolent B-cell non-Hodgkin lymphoma (iNHL) generally require treatment but experience normal survival, emphasizing the need for simpler, safer therapies. Proteasome inhibitors target aberrant signaling pathways within iNHL and have manageable toxicities. We evaluated the oral proteasome inhibitor ixazomib as initial monotherapy, and combined with rituximab, for first-line treatment of iNHL. Treatment-naïve patients with iNHL needing therapy received oral ixazomib 4 mg weekly until progressive disease or unacceptable adverse events. A 4-week course of rituximab was added during month 7. The primary end point was overall response rate (ORR) during the ixazomib monotherapy window. Correlations included gene expression profiling and response to severe acute respiratory syndrome
SUBMITTER: Graf SA
PROVIDER: S-EPMC9984960 | biostudies-literature | 2023 Mar
REPOSITORIES: biostudies-literature
ACCESS DATA